



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/728,423	12/01/2000	Michael Houghton	1618.003	3252

27476 7590 10/01/2002

Chiron Corporation  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097

EXAMINER

HILL, MYRON G

ART UNIT PAPER NUMBER

1648

DATE MAILED: 10/01/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application N .

09/728,423

Applicant(s)

HOUGHTON ET AL.

Examiner

Myron G. Hill

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1- 27 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1- 27 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)                      4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)                      5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6.                      6) ☐ Other: \_\_\_\_\_.

## **DETAILED ACTION**

This office action is on claims 1- 27.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1- 27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In claim 1 it is not clear if the steps recited result in the claimed method and it is not clear if the phrases following the "wherein"s on lines 3 and 4 are optional or meant to define the invention. In claim 3, the art refers to "neutralizing antibodies" and it is not clear if this is what is meant and if the generated Abs are to some other antigens or what they neutralize. It is not clear in claim 6 what the metes and bounds "P7 peptide" is. In claim 7, the metes and bounds of the specified amino acid groups are not defined, the residues should refer to something that defines the specific amino acid residues, a SEQ ID# for example, and the claim recites to "an HCV polypeptide" but claim 1 refers to polynucleotides.

### ***Claim Rejections - 35 USC § 102***

Art Unit: 1648

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in-

(1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or

(2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

Claims 1- 6, 8, 9, and 12- 15 are rejected under 35 U.S.C. 102(e) as being anticipated by O'Hagan (US 6,306,405).

O'Hagan discloses the use of HCV E2 as a DNA immunogen using microparticles to raise an immune response in a mammal (abstract, column 7, lines 50 – 64, columns 8- 14, and claims 1, and 6). E2 is well known in the art to give rise to neutralizing of binding antibodies.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1,2,4,5,9,10,26, and 27 are rejected under 35 U.S.C. 102(b) as being anticipated by Wyatt (J Virol 1998 Mar;72(3):1725-30).

Wyatt teaches an immune response elicited in chimpanzees by the administration of a polynucleotide that encodes a full length E1/E2 polypeptide that were previously infected and presumably seronegative for HCV at initial infection (pages 1725- 1726). Humoral immune response is measured (Figure 2). The challenge

Art Unit: 1648

comprises administering more virus (Table 1) which comprises viral polynucleotide and polyprotein encoded by the polynucleotide.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 10, 11, and 16- 27 rejected under 35 U.S.C. 103(a) as being unpatentable over O'Hagan (US 6,306,405).

O'Hagan as discussed above in the rejection for claims 1- 6, 8, 9, and 12- 15 teaches the use of E2 as a DNA immunogen.

It is well known in the art the use of cardiotoxin is useful in increasing the absorption of DNA immunizations and the use of subsequent immunizations to boost immune response which could be more DNA or protein. It would be obvious to one skilled in the art if the DNA was to be used to raise defined antibodies that it would be administered to subjects that are not infected. E2 is known in the art to rise to strong humoral responses and one of skill in the art would know how to optimize and screen for antibodies that met the "NOB" titers as claimed.

Thus, it would have been *prima facie* obvious to modify the immunogen of O'Hagan with techniques known in the art to improve the results with the expectation of success.

Art Unit: 1648

### ***Conclusion***

No claim is allowed.


The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Inudoh et al. Vaccine 1996, Vol. 14 1590- 1596 and Selby et al US 6,121,020. (both from IDS)

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 703-308-4521. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4247. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Myron G. Hill  
Patent Examiner  
September 29, 2002

  
**MARY E. MOSHER**  
**PRIMARY EXAMINER**  
**GROUP 1800**  
1600